Funder: American Cancer Society
Due Dates: June 1, 2026 (Full application submission for LEAP RFA)
Funding Amounts: Up to $215,000/year (RSG) or $430,000/year (Team Award) in direct costs for up to 4 years, plus 10% indirects; max $946,000 (RSG) or $1,892,000 (Team) total.
Summary: Supports research on mechanisms and prevention strategies for leukemia in patients with RUNX1 familial platelet disorder to accelerate cancer interception and therapy development.
Key Information: Applicants may submit only one application per cycle and must be full-time independent investigators at eligible US institutions.